Related Experiment Video
Updated: Aug 14, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
HIV and hepatitis C virus coinfection: bad bedfellows
1Medicine, University of California San Diego, La Jolla, CA, USA.
Insights
Hepatitis C virus (HCV) infection worsens outcomes for HIV patients, particularly with genotype 1. Current treatments show lower effectiveness in these coinfected individuals.
Area of Science:
- Hepatology and Virology
- Infectious Diseases
- Immunology
Background:
- Hepatitis C virus (HCV) coinfection is prevalent in individuals with human immunodeficiency virus (HIV).
- HIV exacerbates HCV replication and disease progression, increasing morbidity.
- HCV infection complicates antiretroviral therapy for HIV patients.
Purpose of the Study:
- To review the impact of HCV on HIV-infected individuals.
- To discuss current and future treatment strategies for HCV/HIV coinfection.
- To highlight challenges in treating HCV genotype 1 in coinfected populations.
Main Methods:
- Review of existing studies on HCV treatment in coinfected patients.
- Summary of a presentation on HIV/HCV coinfection.
- Discussion of treatment response rates based on HCV genotype.
Main Results:
- Hepatitis C virus genotype 1 is the most common genotype in HCV/HIV-coinfected individuals in the US.
- Peginterferon alfa plus ribavirin therapy yields lower sustained virologic response rates for genotype 1 compared to other genotypes.
- HIV infection accelerates HCV disease progression.
Conclusions:
- HCV/HIV coinfection presents significant challenges in patient management and treatment.
- HCV genotype 1 infection is associated with poorer treatment outcomes in coinfected individuals.
- Further research into novel therapeutic approaches for HCV/HIV coinfection is warranted.
Abstract:
Hepatitis C virus (HCV) infection is common in HIV-infected individuals and is responsible for increasing morbidity in these patients. HIV infection increases HCV replication and accelerates progression of HCV disease. HCV infection increases the risk of antiretroviral treatment. HCV genotype 1 is the predominant genotype in HCV/HIV-coinfected individuals living in the United States. State-of-the-art treatment with peginterferon alfa plus ribavirin results in lower sustained HCV virologic response rates in patients with genotype 1 infection than in those infected with other genotypes. Data from studies of HCV infection treatment in coinfected patients are discussed, as are prospects for future therapy. This article summarizes a presentation on HIV/HCV coinfection by Robert T. Schooley, MD, at the International AIDS Society-USA course in San Francisco in June 2005.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Sexually Transmitted Infections
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Cytomegalovirus Disease
